Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on May 1 and May 2, 2014, for Marathon Patent Group, Inc. (formerly MARA Holdings, Inc.). The filing details a private placement financing transaction and the completion of three intellectual property (IP) acquisitions. The company operates in the patent monetization sector, acquiring IP portfolios to generate revenue through licensing or litigation.
Key Financial Metrics and Capital Structure
- Financing Proceeds: Gross proceeds of $6,503,264 from the sale of 1,000,502 Units (Series A Preferred Stock and Warrants) at $6.50 per unit.
- Debt Obligations: Issuance of promissory notes with an aggregate principal of $5,000,000 (potentially increasing to $6,000,000 if not paid by June 30, 2014), maturing October 30, 2014.
- Acquisition Costs: Immediate cash payments of approximately $5.0 million for IP assets, with potential future contingent payments up to $250,000,000 based on net recoveries.
- Equity Issuance: Issued 1,000,502 shares of Series A Preferred Stock and 391,000 shares of Series B Preferred Stock.
- Outstanding Common Stock: 5,489,593 shares prior to the transactions.
- Placement Fees: $200,000 total fee to Laidlaw & Company (UK) LTD., paid partially in cash and partially in Units.
Material Changes and Transactions
Private Placement (May 1, 2014)
The Company sold Units consisting of 8% Series A Preferred Stock and warrants to purchase 25% of the underlying shares. The warrants have an exercise price of $7.50 and a two-year term. The Series A Preferred Stock carries an 8% annual dividend (payable in cash or stock) and a liquidation preference of $6.50 per share.
Intellectual Property Acquisitions (May 2, 2014)
The Company acquired 100% of the membership interests in three entities holding IP assets:
- Dynamic Advances, LLC: Acquired for $2,375,000 cash (split into two payments) and 195,500 Series B Preferred shares.
- IP Liquidity Ventures, LLC: Acquired for $2,375,000 cash (split into two payments) and 195,500 Series B Preferred shares.
- Sarif Biomedical, LLC: Acquired for $250,000 cash (split into two payments).
Each acquisition includes a "Pay Proceeds Agreement" entitling sellers to 40% of net recoveries between $10M and $40M, and 50% of recoveries above $40M, capped at $250,000,000 total per agreement.
Debt Creation
To fund the second tranche of acquisition payments due by June 30, 2014, the Company issued three promissory notes totaling $5,000,000. These notes carry a penalty clause increasing the principal to $6,000,000 if not paid by the June 30 deadline.
Outlook, Risks, and Management Commentary
- Dilution Risk: Full conversion of Series A and Series B Preferred Stock and exercise of warrants would increase outstanding common shares from 5,489,593 to 7,131,221, representing a significant dilution to existing shareholders.
- Liquidity and Debt Risk: The Company faces a significant near-term liquidity requirement to pay $5,000,000 in promissory notes by June 30, 2014, or face an increase in debt to $6,000,000.
- Dividend Obligation: The Company must pay 8% annual dividends on Series A Preferred Stock starting January 31, 2015. If paid in stock rather than cash, this will cause further dilution.
- Covenants: The Series A Preferred Stock includes restrictive covenants limiting the Company's ability to incur new indebtedness or issue senior stock without holder approval.
- Revenue Contingency: Future revenue is heavily dependent on the success of monetizing the newly acquired IP portfolios, with significant upside potential but no guaranteed returns.
Investor Verification Checklist
- Verify the Company's current cash position and ability to repay the $5,000,000 in promissory notes by June 30, 2014, to avoid the penalty increase.
- Confirm the specific IP assets acquired in the Dynamic Advances, IP Liquidity Ventures, and Sarif Biomedical deals and their litigation or licensing status.
- Review the "Pay Proceeds Agreement" terms to understand the exact definition of "net recoveries" and expense deductions.
- Monitor the effectiveness of the resale registration statement for the Series A Preferred Stock and warrants, required within 60 days of closing.
- Assess the impact of the 8% dividend obligation on future cash flows and the likelihood of stock vs. cash dividend payments.